0.00
—
Close of 30 Oct 2026, in USD
About Bloomios
Its shares trade under the ticker BLMS. It has been listed since 14 October 2003. In the fiscal year to 31 December 2023, it reported revenue of $8.2m and a net loss of $39.6m.
Bloomios, Inc. engages in the manufacture, market, and distribution of U.S. hemp-derived supplements and cosmetic products through wholesale distribution channels and its subsidiary. The company is headquartered in Santa Barbara, California. The company went IPO on 2003-10-14. BPL is engaged in the manufacturing, processing, sourcing and distribution of hemp-derived, nootropic and nutraceutical products to wholesalers and retailers. The firm manufactures hemp infused products ranging from human edibles, pet edibles, liquid consumables such as tinctures and shots, topicals, and smokable hemp. The company provides support at each step from custom formulation, order fulfillment, and brand development. Its product categories include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages and pet treats. The company offers its private-label and white-label customers a collections of customizable hemp products that includes over 80 products across seven categories in addition to custom formulation and manufacturing services.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 14 Oct 2003
- Employees
- 30
- Website
- bloomios.com ↗
Leadership
Pay as last reported
- Mr. Michael HillChairman of the Board, Chief Executive Officer, since 2020$365,000
- Mr. Barrett EvansPresident, Director, Chief Strategy Officer, since 2021$365,000
- Mr. John BennettChief Financial Officer, Director, since 2021$193,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bloomios Inc manufactures hemp-derived supplements and cosmetics in Santa Barbara, US.
- Bloomios offers over 80 customizable hemp products across seven categories for private-label customers.
- Bloomios provides custom formulation, order fulfillment, and brand development support to clients.
Weaknesses
- Bloomios has 30 employees, which may limit scalability in production and distribution.
- Bloomios operates in the U.S. hemp market, which faces regulatory challenges.
- Bloomios IPO was on 14 October 2003, indicating limited market history.
Opportunities
- Bloomios can expand its product categories to include more hemp-derived nutraceuticals and nootropics.
- Bloomios can leverage its 80+ products to enter new international markets like Canada and Europe.
- Bloomios can grow its wholesale distribution channels to reach more retailers and wholesalers.
Threats
- Bloomios faces regulatory risks in the U.S. hemp market due to evolving laws.
- Bloomios competes with other hemp product manufacturers in the U.S. market.
- Bloomios must navigate potential supply chain disruptions affecting hemp sourcing.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.